US declares support for patent waiver on Covid-19 vaccines

Waiver yet to be approved by World Trade Organisation but Biden administration’s position will have strong influence on decision

The US has declared its support for a patent waiver on Covid-19 vaccines to boost their production and distribution around the world.

The waiver will not take place immediately as it has to be approved by consensus at the World Trade Organization (WTO), but the decision of the Biden administration to throw its weight behind a waiver will have a strong influence on the outcome of that decision.

“This is a global health crisis,” Katherine Tai, the US trade representative, said in a written statement. “The extraordinary circumstances of the Covid-19 pandemic call for extraordinary measures.

“The administration strongly believes in intellectual property protections, but in service of ending this pandemic, supports the waiver of those protections for Covid-19 vaccines. We will actively participate in text-based negotiations at the WTO needed to make that happen.”

The announcement was quickly welcomed by the head of the World Health Organization, Tedros Adhanom Ghebreyesus, who described it as a “monumental moment in the fight against Covid-19” and a “powerful example of American leadership to address global health challenges”.

“Now let’s all move together swiftly, in solidarity, building on the ingenuity and commitment of scientists who produced life-saving Covid-19 vaccines,” he said.

The decision was announced during a two-day WTO meeting. India and South Africa have been backing a waiver proposal since October, with the support of about 100 emerging economies, but wealthy countries have been blocking a debate on the issue at the WTO’s Trade-Related Aspects of Intellectual Property Rights (Trips) council.

There is still resistance to a patent waiver in the European Union and Switzerland. A meeting of G7 foreign ministers in London failed to agree on a common position on the issue. A G7 action plan called for greater funding for a UN-administered distribution scheme, Covax, and for voluntary licensing and technology transfer agreements.

Opponents of the waiver within the administration had argued it was not the main bottleneck on production and distribution and that its approval could have a chilling effect on incentives for pharmaceutical companies to produce rapid vaccines in the future. Proponents argued it was an essential move towards greater equity in vaccine distribution and a test of US leadership under Joe Biden’s leadership.

At present, one in four people in rich countries have received at least one vaccine dose. In low-income nations, the ratio is about one in 500 people. “Adoption of this waiver is critical to disseminate vaccine technology to middle-income and low-income nations, so that all people around the world can get access to vaccines and treatment, as quickly as possible,” Paul O’Brien, the executive director of Amnesty International USA, said.

“By reversing the prior administration’s position, President Biden has made clear that the US prioritises people’s lives over pharmaceutical company profits.”


Julian Borger in Washington

The GuardianTramp

Related Content

Article image
Macron voices concerns over Covid vaccines patent waiver
French president says US and UK should start exporting doses around the world instead

Daniel Boffey in Brussels and Kate Connolly in Berlin

07, May, 2021 @3:19 PM

Article image
Mixing Covid vaccines offers strong immune protection – study
Oxford researchers say having AstraZeneca then Pfizer jabs is almost as potent as two shots of Pfizer

Ian Sample and Natalie Grover

28, Jun, 2021 @5:38 PM

Article image
The Covid Delta variant: how effective are the vaccines?
Analysis: what protection do they offer against infection, hospital admission and death?

Nicola Davis Science Correspondent

15, Jun, 2021 @2:38 PM

Article image
Call to prioritise minority ethnic groups for Covid vaccines
BAME communities should be better protected as they are more at risk, say public health experts and MPs

Nazia Parveen, Aamna Mohdin and Niamh McIntyre

18, Jan, 2021 @7:43 PM

Article image
Will Novavax and Johnson & Johnson Covid vaccines work against variants?
Everything you need to know about the trial results for the two new coronavirus vaccines

Archie Bland and Nicola Davis

29, Jan, 2021 @7:05 PM

Article image
UK orders extra Covid vaccines for autumn 2022 booster campaign
Pfizer reportedly asked to supply 35m more doses, with final go-ahead for this year’s programme still awaited

Andrew Sparrow Political correspondent

11, Aug, 2021 @9:51 AM

Article image
Covid vaccines should be available to buy privately in UK, scientists say
People not eligible for autumn booster programme should have option to pay for jab, experts argue, amid new wave concerns

Nicola Davis Science correspondent

17, Aug, 2023 @4:00 AM

Article image
What are the UK’s plans for Covid booster vaccines?
A look at Britain’s booster vaccine programme and whether the science supports an autumn rollout

Nicola Davis

13, Aug, 2021 @1:41 PM

Article image
Covid vaccines may need updating to protect against new variant, study suggests
Neutralising ability of antibodies typically falls eight-fold with South African variant

Ian Sample and Linda Geddes

20, Jan, 2021 @4:15 PM

Article image
What Covid vaccines does the UK have and which are in the works?
As Valneva recruits volunteers for final stage trials of its vaccine, here is the current state of play in Britain

Ian Sample Science editor

25, Apr, 2021 @11:01 PM